<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties manuscript?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">0374630</journal-id><journal-id journal-id-type="pubmed-jr-id">3841</journal-id><journal-id journal-id-type="nlm-ta">Gastroenterology</journal-id><journal-title>Gastroenterology</journal-title><issn pub-type="ppub">0016-5085</issn><issn pub-type="epub">1528-0012</issn></journal-meta><article-meta><article-id pub-id-type="pmid">17484863</article-id><article-id pub-id-type="doi">10.1053/j.gastro.2007.02.051</article-id><article-id pub-id-type="manuscript">wtpa4420</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>IL23R VARIATION DETERMINES SUSCEPTIBILITY BUT NOT DISEASE PHENOTYPE IN INFLAMMATORY BOWEL DISEASE</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tremelling</surname><given-names>M</given-names></name><xref ref-type="author-notes" rid="FN1">*</xref><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cummings</surname><given-names>F</given-names></name><xref ref-type="author-notes" rid="FN1">*</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>SA</given-names></name><xref ref-type="author-notes" rid="FN1">*</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mansfield</surname><given-names>J</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gwilliam</surname><given-names>R</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Keniry</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nimmo</surname><given-names>ER</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Drummond</surname><given-names>H</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Onnie</surname><given-names>CM</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Prescott</surname><given-names>NJ</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sanderson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bredin</surname><given-names>F</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berzuini</surname><given-names>C</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Forbes</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>CM</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cardon</surname><given-names>L</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Deloukas</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Jewell</surname><given-names>D</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mathew</surname><given-names>CG</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Parkes</surname><given-names>M</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Satsangi</surname><given-names>J</given-names></name><xref ref-type="author-notes" rid="FN2">#</xref><xref ref-type="aff" rid="A6">6</xref></contrib></contrib-group><aff id="A1"><label>1</label>IBD research group, Addenbrooke&#x02019;s Hospital, University of Cambridge, Cambridge, UK</aff><aff id="A2"><label>2</label>Gastroenterology Unit, Radcliffe Infirmary, University of Oxford, Oxford, UK</aff><aff id="A3"><label>3</label>Division of Genetics and Molecular Medicine, Guy&#x02019;s, King&#x02019;s College and St Thomas&#x02019; School of Medicine, London, UK</aff><aff id="A4"><label>4</label>Faculty of Medical Sciences, University of Newcastle</aff><aff id="A5"><label>5</label>Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK</aff><aff id="A6"><label>6</label>Dept of Gastroenterology, University of Edinburgh and Gastrointestinal Unit, Western General Hospital, Edinburgh</aff><aff id="A7"><label>7</label>Centre for Gastroenterology and Nutrition, University College, London, UK</aff><aff id="A8"><label>8</label>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">In the authors opinion these authors contributed equally to this research</p></fn><fn fn-type="corresp" id="FN2"><label>#</label><p id="P2">Corresponding author: Professor Jack Satsangi, Gastrointestinal Unit, Division of Medical Sciences, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU UK, Phone: 0131-651-1807 Fax: 0131-537-1085 email: <email>J.Satsangi@ed.ac.uk</email></p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>2</day><month>4</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>2</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>6</month><year>2009</year></pub-date><volume>132</volume><issue>5</issue><fpage>1657</fpage><lpage>1664</lpage><related-article journal-id-type="nlm-ta" journal-id="Gastroenterology" related-article-type="commentary" page="1049" id="N0x1c4f9d0N0x28c2770" xlink:href="17854611" ext-link-type="pubmed" vol="133"/><related-article journal-id-type="nlm-ta" journal-id="Gastroenterology" related-article-type="commentary" page="2045" id="N0x1c4f9d0N0x28c2698" xlink:href="17484895" ext-link-type="pubmed" vol="132"/><abstract><sec id="S1"><title>Background &#x00026; Aims</title><p id="P3">Identification of inflammatory bowel disease (IBD) susceptibility genes is key to understanding pathogenic mechanisms. Recently the North American IBD Genetics Consortium provided compelling evidence for association between ileal Crohn&#x02019;s disease (CD) and the <italic>IL23R</italic> gene using genome-wide association scanning. External replication is a priority, both to confirm this finding in other populations, and to validate this new technique. We tested for association between <italic>IL23R</italic> and IBD in a large independent UK panel, to determine the size of the effect and explore sub-phenotype correlation and interaction with CARD15.</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><p id="P4">8 SNP markers in <italic>IL23R</italic> tested in the North American study were genotyped in 1902 CD cases, 975 with ulcerative colitis (UC), and 1345 controls using MassARRAY (Sequenom). Data were analysed using chi-squared statistics and subgroup association was sought.</p></sec><sec id="S3"><title>Results</title><p id="P5">Highly significant association with CD was observed with the strongest signal at coding variant Arg381Gln - allele frequency 2.5% in CD vs 6.2% in controls (p=1.1&#x000d7;10<sup>-12</sup>) odds ratio 0.38 [95% CI 0.29, 0.50]. A weaker effect was seen in UC -allele frequency 4.6% odds ratio 0.73 [95% CI 0.55, 0.96]. Analysis accounting for Arg381Gln suggested other loci within IL23R also influence IBD susceptibility. Within CD there were no sub-phenotype associations, nor evidence of interaction with <italic>CARD15</italic>.</p></sec><sec id="S4"><title>Conclusions</title><p id="P6">This study demonstrates association between <italic>IL23R</italic> and all subphenotypes of CD with a smaller effect on UC. This extends the findings of the North American study providing clear evidence that genome-wide association scanning can successfully identify true complex disease genes.</p></sec></abstract><contract-num rid="WT3">077011</contract-num><contract-num rid="WT3">068545</contract-num><contract-num rid="MRC_3">G0000934(68341)</contract-num><contract-sponsor id="WT3">Wellcome Trust</contract-sponsor><contract-sponsor id="MRC_3">Medical Research Council</contract-sponsor></article-meta></front><body><sec sec-type="intro" id="S5"><title>INTRODUCTION</title><p id="P7">It is widely recognized that knowledge regarding the genetic basis of inflammatory bowel disease (IBD) and other complex diseases will provide key insights into pathogenic mechanisms. It is this fact that has spurred efforts to identify disease susceptibility genes. Of the many complex diseases investigated using molecular genetic techniques, Crohn&#x02019;s disease (CD) is exceptional in that specific genetic variants unequivocally associated with disease susceptibility have been successfully identified.<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref> Nonetheless characterization of the unknown number of remaining CD genes is required to complete the picture, and remains a priority.</p><p id="P8">CD is one of the two common and related forms of IBD, the other being ulcerative colitis (UC). Within the UK they have a combined prevalence of approximately 4/1000.<xref ref-type="bibr" rid="R3">3</xref> Both are known to have a significant genetic contribution to their aetiology, but this is stronger for CD than UC.<xref ref-type="bibr" rid="R4">4</xref> The epidemiological evidence also suggests that CD and UC share some susceptibility genes. In 2001 fine mapping of a widely replicated linkage region on chromosome 16 led to the identification of <italic>CARD15</italic> as a major CD susceptibility gene, with mutations leading to dysregulation of innate immune pathways.<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref> CARD15 genes have subsequently been shown in meta-analysis to predominantly determine susceptibility to ileal CD. Variants within a number of other genes have been associated with CD, UC or both<xref ref-type="bibr" rid="R5">5</xref>-<xref ref-type="bibr" rid="R9">9</xref> although their exact roles in IBD susceptibility require clarification and in some cases replication.</p><p id="P9">To date pinpointing of disease genes has depended on detailed evaluation of candidates implicated by their function or patterns of expression, or by fine-mapping within large regions identified in the course of genome-wide linkage scans. Across the range of common diseases productivity of such approaches has been limited. Most complex disease genetic studies - including many in IBD - have been beset by poor reproducibility of results and slow progress in identifying disease genes. This has been attributed to a range of factors, some of the most important being the low resolution of sib-pair linkage analysis, use of inappropriate statistical thresholds for significance, and poor matching of controls due to population admixture<xref ref-type="bibr" rid="R10">10</xref>.</p><p id="P10">One powerful new method for the identification of complex disease genes is genome-wide association scanning, genotyping large panels of affected individuals and appropriately matched population controls for hundreds of thousands of polymorphic markers across the genome and using appropriately stringent statistical thresholds for significance<xref ref-type="bibr" rid="R11">11</xref>. Within the past year such studies have become technically and financially possible using sets of markers which capture most common variation across the genome using knowledge regarding human haplotype structure available from the International Hapmap Project (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">http://www.hapmap.org</ext-link>)<xref ref-type="bibr" rid="R12">12</xref> Systematic whole-genome association studies, in comparison to the previous gold-standard of linkage analysis, should provide substantially increased power and resolution for detection of complex disease susceptibility genes.<xref ref-type="bibr" rid="R13">13</xref></p><p id="P11">Recently the results of a 308,332 marker genome scan in a North American panel of 547 non-Jewish CD cases and 548 controls was reported. Cases were selected as having ileal CD to reduce heterogeneity. <xref ref-type="bibr" rid="R14">14</xref> Three markers showed highly significant association with CD, two of which were in <italic>CARD15</italic>. The third marker was a rare coding variant rs11209026c (1142G&#x0003e;A; Arg381Gln) found in the interleukin 23 receptor (<italic>IL23R</italic>) gene on chromosome 1 (P=5.05 &#x000d7; 10<sup>-9</sup>). Nine other markers showed association with P &#x0003c;0.0001 either within <italic>IL23R</italic> or in the intergenic area with the adjacent <italic>IL12RB2</italic> gene. Internal replication was achieved in the index study using both a Jewish CD case-control cohort (peak P-value 3.36 &#x000d7; 10<sup>-13</sup>) and family based methodologies, the latter in addition suggesting association with UC in a small non-Jewish cohort. This finding indicates that <italic>IL23R</italic> may have a general role in the aetiology of IBD.<xref ref-type="bibr" rid="R14">14</xref> The aims of the current study were to seek replication of the association between <italic>IL23R</italic> and IBD in a large independent North European cohort representing the full range of CD and UC phenotypes, examine in detail genotype-phenotype relationships, explore evidence for epistasis with the known CD susceptibility gene <italic>CARD15</italic>, and to provide accurate estimates of disease risk for associated variants. Replication of the association in an independent cohort would serve two important purposes. Firstly it is key to confirming the veracity of the original finding and the applicability of these findings in populations outside North America. Further, strong independent replication of the key finding of one of the first published genome wide association scans would provide proof of principle that this novel methodology can be used to identify risk variants for complex diseases.</p></sec><sec sec-type="materials|methods" id="S6"><title>MATERIALS AND METHODS</title><sec sec-type="subjects" id="S7"><title>Subjects</title><p id="P12">2877 individuals with IBD (1902 CD, 975 UC) were recruited in five centres across England and Scotland. The study was approved by the Research Ethics Committees at each centre.</p><p id="P13">Standard clinical, radiological and histological diagnostic criteria were applied.<xref ref-type="bibr" rid="R15">15</xref> Phenotypic details were obtained by retrospective case notes review. CD phenotype was classified by age of diagnosis, location and behaviour of disease. Only one member of multiply affected families was included. 1.75% were of Jewish origin and 2.25% were non-Caucasian. Demographic and sub phenotype data are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p><p id="P14">Control allele frequencies were obtained from 1345 individuals recruited across Britain as part of the 1958 British Birth cohort.<xref ref-type="bibr" rid="R16">16</xref> Cases and controls were categorised into 12 broad geographical regions within Great Britain in order to minimize confounding due to variation in allele frequencies across the country.<xref ref-type="bibr" rid="R17">17</xref></p></sec><sec id="S8"><title>Genotyping</title><p id="P15">Genotyping of cases was undertaken with iPLEX chemistry on a MALDI-TOF MassARRAY platform (Sequenom, San Diego, CA). Cases were genotyped for 8 <italic>IL23R</italic> markers reported in the index study including the non-synonymous SNP rs11209026 encoding amino acid change Arg381Gln. (primer sequences in <xref ref-type="supplementary-material" rid="SD1">Supplementary Data Table 1</xref>.) Two of the US markers (rs7517847, rs2201841) were omitted due to their location within a sequence of interspersed low complexity repeats.</p><p id="P16">Genotyping of controls was undertaken at the Wellcome Trust Sanger Institute using the Illumina 550K chip (Illlumina, San Diego, USA). Concordance of genotype calls between the different platforms was confirmed by genotyping 87 control DNAs for all 8 markers using the MassARRAY platform with strong concordance of calls between technologies -98.99% for the 8 markers overall. There was 100% concordance for 3 markers including the coding variant Arg381Gln (<xref ref-type="supplementary-material" rid="SD1">Supplementary Data Table 2</xref>). The data for 1594 CD cases genotyped for <italic>CARD15</italic> mutations in earlier studies were used to undertake analysis for evidence of interaction between <italic>CARD15</italic> and <italic>IL23R.</italic><sup><xref ref-type="bibr" rid="R18">18</xref>-<xref ref-type="bibr" rid="R21">21</xref></sup></p></sec><sec sec-type="methods" id="S9"><title>Statistical Methods</title><p id="P17">Allele frequencies were compared between cases and controls and between phenotypic subgroups using chi-squared tests of 2&#x000d7;2 tables. Odds ratios were calculated for the minor allele at each SNP; confidence intervals were calculated using Woolf&#x02019;s method.<xref ref-type="bibr" rid="R22">22</xref> Pairwise SNP linkage disequilibrium coefficients were estimated using Haploview.<xref ref-type="bibr" rid="R23">23</xref> Conditional association analysis was implemented using COCAPHASE, a module of the UNPHASED program.<xref ref-type="bibr" rid="R24">24</xref> This method tests for equality of odds ratios for haplotypes identical at conditioning loci. The Mantel-Haenszel test for association conditioning on geographical region was implemented using PLINK (<ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/~purcell/plink/">http://pngu.mgh.harvard.edu/~purcell/plink/</ext-link>). Median age at disease diagnosis between groups was compared using Wilcoxon&#x02019;s rank sum test. Age at diagnosis was dichotomized according to the Montreal Classification.<xref ref-type="bibr" rid="R25">25</xref> Unless specified otherwise, all analyses were carried out using R v2.2 for Windows (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org.">http://www.R-project.org.</ext-link>)</p></sec></sec><sec sec-type="results" id="S10"><title>RESULTS</title><p id="P18">All genotypes were in Hardy Weinberg equilibrium in both cases and controls (p&#x0003e;0.05). Highly significant association with CD was observed across the region (<xref ref-type="table" rid="T2">Table 2</xref>). The strongest association was observed at the non-synonymous SNP Arg381Gln where the frequency of the A allele was 2.5% in CD compared with 6.2% in controls (p=1.1&#x000d7;10<sup>-12</sup>). The odds ratio for this protective allele was 0.38 [95% CI 0.29, 0.50]. Alternatively, the common wildtype homozygous GG genotype can be considered as the risk genotype with an odds ratio of 2.70. To minimise potential confounding from regional differences in allele frequencies, a Mantel-Haenszel test was carried out across 12 regional strata. Mantel-Haenszel odds ratios was very similar to those obtained from pooled data for all SNPs. For example, OR <sub>M-H</sub> = 0.36 [95% CI 0.25, 0.51] for Arg381Gln.</p><p id="P19">Several SNPs also showed significant association with UC (<xref ref-type="table" rid="T2">Table 2</xref>). The strongest signal was observed with common SNPs rs1004819 (p=0.0071) and rs10889677 (p=0.0042). The frequency of Arg381Gln was only marginally different between cases and controls (UC: 0.046 vs controls: 0.062; p=0.029) with an odds ratio of 0.73 [95% CI 0.55, 0.96].</p><p id="P20">The non-synonymous SNP Arg381Gln was in tight LD with one other SNP (rs11465804 r<sup>2</sup> 0.85) but weak LD with all 6 other SNPs (r<sup>2</sup> 0.03-0.1). A separate test for CD association was performed for each SNP conditioning on Arg381Gln by conditional regression modelling. This showed a significant association at all SNPs (p&#x0003c;0.001) except rs11465804, the strongest residual association being detected at rs10889677 (p=4.6&#x000d7;10<sup>-8</sup>). Hence the non-synonymous SNP does not account for all the association signal at this locus.</p><p id="P21">Data were then analysed for evidence of significant genotype-phenotype correlations based on age at onset of CD, disease location and disease behaviour (<xref ref-type="table" rid="T3">Table 3</xref>). No significant sub-group association was observed. In particular, the sub-group of patients with CD affecting the colon only without small bowel disease (n=539) appeared to be as strongly associated as those with exclusively ileal/small bowel involvement (n=668) (minor allele frequencies 2.3% and 2.0% respectively). The age at disease onset ranged from 12-67 in CD cases who carried the A allele of Arg381Gln and 0-80 in wildtype GG cases. There was no difference in the median age of onset between these two groups (AA/AG: median = 28 years, n=85; GG: median = 26 years, n=1650; p=0.26). Stratification of cases by age at diagnosis according to the Montreal Classification.<xref ref-type="bibr" rid="R25">25</xref> revealed similar genotype frequencies in all groups (<xref ref-type="table" rid="T3">Table 3</xref>). For UC, subgroup analysis by disease extent, smoking history and gender also revealed no significant subgroup association. Age at UC onset ranged from 14-79 in cases who carried the A allele of Arg381Gln and 2-81 in wildtype GG cases with no difference in the median age of onset between the two groups (AA/AG: median = 34 years, n=72; GG: median = 33 years, n=708; p=0.14). (<xref ref-type="table" rid="T4">Table 4</xref>.) A total of 1540 CD cases were fully genotyped for the three <italic>CARD15</italic> mutations (G908R, L1007fs, R702W) (<xref ref-type="table" rid="T3">Table 3</xref>). The frequency of Arg381Gln in 460 cases carrying at least one <italic>CARD15</italic> mutation (2.2%) was not significantly different from that in 1081 cases who carried none (2.7%, p=0.47). None of the three cases who were homozygous for the rare A allele also carried a <italic>CARD15</italic> mutation.</p></sec><sec sec-type="discussion" id="S11"><title>DISCUSSION</title><p id="P22">This study provides unequivocal confirmation of association between variants in the <italic>IL23R</italic> gene and inflammatory bowel disease, suggesting a major effect on overall susceptibility to CD and a more modest effect on UC. Importantly this study also demonstrates the association at <italic>IL23R</italic> for the first time in a non-American population. The strength of this association at <italic>IL23R</italic> and the fact that it reaches such a magnitude in two independent datasets leaves no doubt that it is a true finding. In addition this is one of the first instances of highly significant, independent replication of data derived from a genome-wide association scan, and provides important validation of this technique as a hypothesis free method for the identification of complex disease genes.</p><p id="P23">As with the North American genome-wide scan, the strongest evidence for association was seen at the non-synonymous SNP Arg381Gln where the frequency of the A allele was 2.5% in CD compared with 6.2% in controls (p=1.1&#x000d7;10<sup>-12</sup>). These allele frequencies are similar to those seen in the North American panel.<xref ref-type="bibr" rid="R14">14</xref> There was no evidence that <italic>IL23R</italic> variants associate with any particular sub-phenotype of CD based on disease behaviour or location. Hence there was no difference in MAF even between the extremes of pure ileal / small bowel CD and pure colonic CD (2.7 and 2.3% respectively). Likewise, analysis based on disease behaviour does not reveal any specific sub-group associations (<xref ref-type="table" rid="T3">Table 3</xref>). This negative result is interesting as it contrasts with the other confirmed CD susceptibility locus CARD15 which seems to have definite associations with ileal disease.<xref ref-type="bibr" rid="R26">26</xref> These findings are extended by the observation of association with UC overall but not with any known UC sub-phenotype group, suggesting that <italic>IL23R</italic> variants may exert a rather generic effect on chronic intestinal inflammation - although the effect size in UC does appear to be smaller than in CD. It is noteworthy that the odds ratio confidence interval at Arg381Gln for UC (0.73 [95% CI 0.55, 0.96]) does not overlap with that for CD (0.38 [95% CI 0.29, 0.50]) suggesting a significantly less marked protective effect of the rare allele for UC compared with CD.</p><p id="P24">Based on data from our large, independent panel of CD cases it is possible to provide an accurate estimate of the size of the effect conferred by <italic>IL23R</italic> variants with regard to the risk of CD. We estimated an odds ratio of 0.38 [95% CI 0.29, 0.49] for Arg381Gln. This is likely to be a more accurate estimate than that provided in the index report from the North American study (OR=0.26 95%CI [0.15-0.43]) due to the well recognized bias of the so-called &#x0201c;winner&#x02019;s curse&#x0201d; which leads to over-estimation of effect size in discovery panels.<xref ref-type="bibr" rid="R27">27</xref> Characterizing the exact effect size is important to permit sample size calculation for any further attempts at replication. Where the effect size is over-estimated there is a risk that apparently appropriately powered studies will fail to observe the effect and erroneously conclude that it is a false positive.</p><p id="P25">In some previous reports of genetic association effect sizes have been quantitated as a population attributable risk (PAR) in addition to the odds ratio. This figure is intended to estimate the proportion of disease incidence attributable to a specific variant. However, it cannot be calculated for a protective minor allele as in the case of Arg381Gln. Further, while it is possible to think of the effect at Arg381Gln as an increased risk conferred by the common G allele, calculations of PAR based on this assumption lead to an implausibly high figure due to the very high carriage rate of the G allele in the control population.</p><p id="P26">One important question is whether the non-synonymous variant accounts for all of the association signal at <italic>IL23R</italic>. This was tested by conditional regression modeling - looking for evidence of association while controlling for the effect at Arg381Gln. From this analysis it is clear that there is a strong residual signal, maximal at rs10889677 (p=4.6&#x000d7;10<sup>-8</sup>) and hence that variation at loci in addition to Arg381Gln, either within or adjacent to <italic>IL23R</italic>, exert an influence on IBD susceptibility. Whether this reflects a functional impact of the non-coding variants themselves or the fact that they are in LD with other functionally significant or coding variants is yet to be established. Analysis within haploview (<ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview/">http://www.broad.mit.edu/mpg/haploview/</ext-link>) of data available from The International HapMap Project<xref ref-type="bibr" rid="R28">28</xref> (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">www.hapmap.org</ext-link> accessed 18/1/2007) demonstrates that this selection of 8 tag SNPs captures only 18 out of 83 informative SNPs, within <italic>IL23R</italic> and the 3&#x02032; intergenic region covered by these markers, genotyped in the CEPH (Utah residents with ancestry from northern and western Europe) panel at r<sup>2</sup>&#x0003e;0.8. Any additional coding variation is likely to be rare as interrogation of Ensembl database release 41 (October2006) (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/">http://www.ensembl.org/</ext-link>) reveals the presence of only two additional non-synonymous coding variants (rs1884444 and rs7530511) in <italic>IL23R</italic> with MAF &#x0003e; 1% in healthy European populations, both of which were investigated in the North American study with neither showing evidence of association. However, it is known that different splice isoforms of <italic>IL23R</italic> exist and it is possible that their expression is determined by some of the documented non-coding variation.<xref ref-type="bibr" rid="R29">29</xref> To clarify these issues future studies will need to include re-sequencing of <italic>IL23R</italic> in a CD panel and fine mapping across the gene using markers identified as a result, as well as studies to assess the potential functional impact of variants identified.</p><p id="P27">The data with regard to Arg381Gln provide evidence of a very common variant being a disease risk allele, or conversely protection from CD being conferred by the rare allele. The explanations are likely to be complex but for immune mediated conditions may include the fact that genetic variation at a particular locus confers a spectrum of risk - being protective against some diseases, such as infections, while increasing the risk of others, such as autoimmunity or inflammatory conditions. These variations will have been subject to differing selection pressures in diverse populations as a result of different environmental exposures. It is also noteworthy that for some of the markers showing evidence of association it is the rarer allele that is associated with increased risk of CD. This further supports the argument for more than one variant in <italic>IL23R</italic> with different effects on gene function.</p><p id="P28">Recent studies have identified IL-23, the cognate ligand of <italic>IL23R</italic>, as a key player in both innate and adaptive immune systems. Most IL-23 is secreted by activated dendritic cells, monocytes and macrophages following their exposure to pathogen-derived molecules which bind at toll-like receptors.<xref ref-type="bibr" rid="R30">30</xref> IL-23 stimulates a unique CD4+ helper T cell population characterized by the production of IL-17, TNF and IL-6, and known as Th17 cells. These cells play a central role in driving autoimmune inflammation in a number of animal models. IL-17 stimulates monocytes and endothelial cells to produce pro-inflammatory mediators which in turn promote rapid neutrophil recruitment.<xref ref-type="bibr" rid="R30">30</xref> The effect of IL-23 has recently been distinguished from that of the related hetero-dimer IL-12 with which it shares a common p40 subunit.<xref ref-type="bibr" rid="R31">31</xref> Importantly in this regard two studies in knockout mice lacking the p19 subunit of IL-23 demonstrated marked attenuation of T-cell mediated colitis whilst knockout of the p35 subunit of IL-12 produces no such attenuation, suggesting that IL-23 but not IL-12 is essential for the development of colitis.<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R33">33</xref> The identification of different roles for IL-12 and IL-23 in control of immune pathways together with the current genetic data suggest that targeting IL-23 (and components of it&#x02019;s downstream effector pathway) may be a useful and specific strategy to inhibit IBD while sparing systemic host protective immunity.<xref ref-type="bibr" rid="R34">34</xref></p><p id="P29">As well as focussing attention on the IL-23 pathway in the pathogenesis of IBD, the current study also provides key validation of genome-wide association scanning as a means of identifying complex disease susceptibility genes. The North American study group applied an appropriate, genome-wide significance level and use of such a stringent threshold has immediately led to replication in our independent panel - with a level of significance which makes the association indisputable.</p><p id="P30">To date complex disease genetic studies have been beset by poor study design, particularly use of non-conservative thresholds for significance, resulting in publication of many unreplicated false-positive results across the spectrum of common disease. Hence the importance of the current study in providing unequivocal early replication in an independent panel of the principal findings from one of the first reported genome-wide association scans. There are recent reports in another complex disease (age-related macular degeneration) which also provide grounds for optimism that this technique produces replicable genetic association data.<xref ref-type="bibr" rid="R35">35</xref>-<xref ref-type="bibr" rid="R37">37</xref> The clear message is that genome-wide association scanning works - and that this study design, which is being so vigorously applied across a number of common diseases, is likely to be highly productive. The hope is that with use of appropriately stringent statistical thresholds and appropriately powered datasets the success seen here in CD will be generally applicable, without the plethora of false positive results that have vexed the field of complex disease genetics to date.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="NIHMS4420-supplement-1.pdf" xlink:type="simple" id="N0x1c8b570N0x2ade000" position="anchor" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec></body><back><ack id="S12"><title>Acknowledgements</title><p>We acknowledge use of DNA from the 1958 British Birth Cohort collection (R. Jones, S. Ring, W. McArdle and M. Pembrey), funded by the Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02. We would also like to acknowledge the National Association for Colitis and Crohn&#x02019;s disease and the Wellcome Trust for supporting the case DNA collections, and the Wellcome Trust Case Control Consortium for which the CD panel was originally assembled. We would also like to thank all the subjects who contributed samples, and the consultants and nursing staff across the UK who helped with recruitment of study subjects: C Todhunter, A Sutherland, K Mohiuddin, N Thompson, M Hudson, J Barbour, P Donaldson, SJ Middleton, J Woodward, J Hunter, RS Harvey, JH Saunders, A Douds, D Sharpstone, S Whalley, A Nicolson, SM Greenfield, PB McIntyre, MJ Carter, I Barrison, HJ Kennedy, IW Fellows, R Tighe, MG Phillips, C Jamieson, I Beales, A Hart, A Prior, J Wyke, S Williams, Y Miao, M Ninkovic, M Dronfield, P Nair, R Dickinson, P Roberts, CP Willoughby, I Dunkley, D Morris, M Twist, N Fisher, D Kelf and A Nightingale, C W Lees, G T Ho, I D Arnott, T Ahmad, D McGovern, J Beckly, R Cooney, L Hancock, A Geramia, S Goldthorpe and S Patham.</p></ack><fn-group><fn id="FN3"><p id="P31">Conflicts of interest: There are no conflicts to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>Bonen</surname><given-names>DK</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Chen</surname><given-names>FF</given-names></name><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Britton</surname><given-names>H</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Karaliuskas</surname><given-names>R</given-names></name><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Achkar</surname><given-names>JP</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Bayless</surname><given-names>TM</given-names></name><name><surname>Kirschner</surname><given-names>BS</given-names></name><name><surname>Hanauer</surname><given-names>SB</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name></person-group><article-title>A frameshift mutation in NOD2 associated with susceptibility to Crohn&#x02019;s disease</article-title><source>Nature</source><year>2001</year><volume>411</volume><issue>6837</issue><fpage>603</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11385577</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hugot</surname><given-names>JP</given-names></name><name><surname>Chamaillard</surname><given-names>M</given-names></name><name><surname>Zouali</surname><given-names>H</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Cezard</surname><given-names>JP</given-names></name><name><surname>Belaiche</surname><given-names>J</given-names></name><name><surname>Almer</surname><given-names>S</given-names></name><name><surname>Tysk</surname><given-names>C</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>CA</given-names></name><name><surname>Gassull</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>V</given-names></name><name><surname>Finkel</surname><given-names>Y</given-names></name><name><surname>Cortot</surname><given-names>A</given-names></name><name><surname>Modigliani</surname><given-names>R</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Gower-Rousseau</surname><given-names>C</given-names></name><name><surname>Macry</surname><given-names>J</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Sahbatou</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn&#x02019;s disease</article-title><source>Nature</source><year>2001</year><volume>411</volume><issue>6837</issue><fpage>599</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">11385576</pub-id></citation></ref><ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>MA</given-names></name><name><surname>Mayberry</surname><given-names>JF</given-names></name><name><surname>Baker</surname><given-names>R</given-names></name></person-group><article-title>Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England</article-title><source>European Journal of Gastroenterology &#x00026; Hepatology</source><year>2003</year><volume>15</volume><issue>12</issue><fpage>1275</fpage><lpage>1280</lpage><pub-id pub-id-type="pmid">14624149</pub-id></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tysk</surname><given-names>C</given-names></name><name><surname>Lindberg</surname><given-names>E</given-names></name><name><surname>Jarnerot</surname><given-names>G</given-names></name><name><surname>Floderus-Myrhed</surname><given-names>B</given-names></name></person-group><article-title>Ulcerative colitis and Crohn&#x02019;s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking</article-title><source>Gut</source><year>1988</year><volume>29</volume><issue>7</issue><fpage>990</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3396969</pub-id></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name></person-group><article-title>Role of the IBD5 susceptibility locus in the inflammatory bowel diseases</article-title><source>Inflamm Bowel Dis</source><year>2006</year><volume>12</volume><issue>3</issue><fpage>227</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16534425</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Paolucci</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Jewell</surname><given-names>D</given-names></name><name><surname>Cardon</surname><given-names>L</given-names></name><name><surname>Takazoe</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Ichimori</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><article-title>Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn&#x02019;s disease</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><issue>22</issue><fpage>3499</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">16221758</pub-id></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>G-T</given-names></name><name><surname>Nimmo</surname><given-names>ER</given-names></name><name><surname>Tenesa</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>J</given-names></name><name><surname>Drummond</surname><given-names>H</given-names></name><name><surname>Mowat</surname><given-names>C</given-names></name><name><surname>Arnott</surname><given-names>ID</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name></person-group><article-title>Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis</article-title><source>Gastroenterology</source><year>2005</year><volume>128</volume><issue>2</issue><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">15685540</pub-id></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franchimont</surname><given-names>D</given-names></name><name><surname>Vermeire</surname><given-names>S</given-names></name><name><surname>El Housni</surname><given-names>H</given-names></name><name><surname>Pierik</surname><given-names>M</given-names></name><name><surname>Van Steen</surname><given-names>K</given-names></name><name><surname>Gustot</surname><given-names>T</given-names></name><name><surname>Quertinmont</surname><given-names>E</given-names></name><name><surname>Abramowicz</surname><given-names>M</given-names></name><name><surname>Van Gossum</surname><given-names>A</given-names></name><name><surname>Deviere</surname><given-names>J</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name></person-group><article-title>Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn&#x02019;s disease and ulcerative colitis</article-title><source>Gut</source><year>2004</year><volume>53</volume><issue>7</issue><fpage>987</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15194649</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Corneliussen</surname><given-names>B</given-names></name><name><surname>Costello</surname><given-names>CM</given-names></name><name><surname>Waetzig</surname><given-names>GH</given-names></name><name><surname>Mellgard</surname><given-names>B</given-names></name><name><surname>Koch</surname><given-names>WA</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Albrecht</surname><given-names>M</given-names></name><name><surname>Croucher</surname><given-names>PJ</given-names></name><name><surname>Seegert</surname><given-names>D</given-names></name><name><surname>Nikolaus</surname><given-names>S</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Lengauer</surname><given-names>T</given-names></name><name><surname>Pierrou</surname><given-names>S</given-names></name><name><surname>Foelsch</surname><given-names>UR</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Lagerstrom-Fermer</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name></person-group><article-title>Genetic variation in DLG5 is associated with inflammatory bowel disease</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><issue>5</issue><fpage>476</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15107852</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name></person-group><article-title>Association study designs for complex diseases</article-title><source>Nat Rev Genet</source><year>2001</year><volume>2</volume><issue>2</issue><fpage>91</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11253062</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Risch</surname><given-names>N</given-names></name><name><surname>Merikangas</surname><given-names>K</given-names></name></person-group><article-title>The future of genetic studies of complex human diseases</article-title><source>Science</source><year>1996</year><volume>273</volume><issue>5281</issue><fpage>1516</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8801636</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name></person-group><article-title>Evaluating coverage of genome-wide association studies</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><issue>6</issue><fpage>659</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16715099</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Genome-wide association studies for common diseases and complex traits</article-title><source>Nat Rev Genet</source><year>2005</year><volume>6</volume><issue>2</issue><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15716906</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Abraham</surname><given-names>C</given-names></name><name><surname>Regueiro</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>A</given-names></name><name><surname>Dassopoulos</surname><given-names>T</given-names></name><name><surname>Bitton</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Targan</surname><given-names>S</given-names></name><name><surname>Datta</surname><given-names>LW</given-names></name><name><surname>Kistner</surname><given-names>EO</given-names></name><name><surname>Schumm</surname><given-names>LP</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Barmada</surname><given-names>MM</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name></person-group><article-title>A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene</article-title><source>Science</source><year>2006</year></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lennard-Jones</surname><given-names>JE</given-names></name></person-group><article-title>Classification of inflammatory bowel disease</article-title><source>Scand J Gastroenterol Suppl</source><year>1989</year><volume>170</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2617184</pub-id></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name></person-group><article-title>Cohort profile: 1958 British birth cohort (National Child Development Study)</article-title><source>Int. J. Epidemiol</source><year>2006</year><volume>35</volume><issue>1</issue><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16155052</pub-id></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Smyth</surname><given-names>DJ</given-names></name><name><surname>Pask</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Maier</surname><given-names>LM</given-names></name><name><surname>Smink</surname><given-names>LJ</given-names></name><name><surname>Lam</surname><given-names>AC</given-names></name><name><surname>Ovington</surname><given-names>NR</given-names></name><name><surname>Stevens</surname><given-names>HE</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name><name><surname>Faham</surname><given-names>M</given-names></name><name><surname>Moorhead</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>HB</given-names></name><name><surname>Falkowski</surname><given-names>M</given-names></name><name><surname>Hardenbol</surname><given-names>P</given-names></name><name><surname>Willis</surname><given-names>TD</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name></person-group><source>Population structure, differential bias and genomic control in a large-scale, case-control association study</source><year>2005</year><volume>37</volume><issue>11</issue><fpage>1243</fpage><lpage>1246</lpage></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waller</surname><given-names>S</given-names></name><name><surname>Tremelling</surname><given-names>M</given-names></name><name><surname>Bredin</surname><given-names>F</given-names></name><name><surname>Godfrey</surname><given-names>L</given-names></name><name><surname>Howson</surname><given-names>J</given-names></name><name><surname>Parkes</surname><given-names>M</given-names></name></person-group><article-title>Evidence for association of OCTN genes and IBD5 with ulcerative colitis</article-title><source>Gut</source><year>2006</year><volume>55</volume><issue>6</issue><fpage>809</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16361305</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>AV</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Onnie</surname><given-names>CM</given-names></name><name><surname>Pattni</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>P</given-names></name><name><surname>Forbes</surname><given-names>A</given-names></name><name><surname>Mansfield</surname><given-names>J</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name></person-group><article-title>Investigation of association of the DLG5 gene with phenotypes of inflammatory bowel disease in the British population</article-title><source>Int J Colorectal Dis</source><year>2006</year></citation></ref><ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnott</surname><given-names>ID</given-names></name><name><surname>Nimmo</surname><given-names>ER</given-names></name><name><surname>Drummond</surname><given-names>HE</given-names></name><name><surname>Fennell</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>BR</given-names></name><name><surname>MacKinlay</surname><given-names>E</given-names></name><name><surname>Morecroft</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>N</given-names></name><name><surname>Kelleher</surname><given-names>D</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M</given-names></name><name><surname>McManus</surname><given-names>R</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name></person-group><article-title>NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn&#x02019;s disease patients: evidence for genetic heterogeneity within Europe?</article-title><source>Genes Immun</source><year>2004</year><volume>5</volume><issue>5</issue><fpage>417</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15190267</pub-id></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Tamboli</surname><given-names>CP</given-names></name><name><surname>Jewell</surname><given-names>D</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name></person-group><article-title>Clinical relevance of advances in genetics and pharmacogenetics of IBD</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><issue>6</issue><fpage>1533</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15168365</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>B</given-names></name></person-group><article-title>On estimating the relation between blood group and disease</article-title><source>Ann Hum Genet</source><year>1955</year><volume>19</volume><issue>4</issue><fpage>251</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">14388528</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><issue>2</issue><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudbridge</surname><given-names>F</given-names></name></person-group><article-title>Pedigree disequilibrium tests for multilocus haplotypes</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><issue>2</issue><fpage>115</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12916020</pub-id></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Arnott</surname><given-names>ID</given-names></name><name><surname>Bernstein</surname><given-names>CN</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Caprilli</surname><given-names>R</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Gasche</surname><given-names>C</given-names></name><name><surname>Geboes</surname><given-names>K</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name><name><surname>Karban</surname><given-names>A</given-names></name><name><surname>Loftus</surname><given-names>EV</given-names><suffix>Jr</suffix></name><name><surname>Pena</surname><given-names>AS</given-names></name><name><surname>Riddell</surname><given-names>RH</given-names></name><name><surname>Sachar</surname><given-names>DB</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Targan</surname><given-names>SR</given-names></name><name><surname>Vermeire</surname><given-names>S</given-names></name><name><surname>Warren</surname><given-names>BF</given-names></name></person-group><article-title>Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology</article-title><source>Can J Gastroenterol</source><year>2005</year><volume>19</volume><issue>Suppl A</issue><fpage>5</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16151544</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Economou</surname><given-names>M</given-names></name><name><surname>Trikalinos</surname><given-names>TA</given-names></name><name><surname>Loizou</surname><given-names>KT</given-names></name><name><surname>Tsianos</surname><given-names>EV</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>Differential Effects of NOD2 Variants on Crohn&#x02019;s Disease Risk and Phenotype in Diverse Populations: A Metaanalysis</article-title><source>The American Journal of Gastroenterology</source><year>2004</year><volume>99</volume><issue>12</issue><fpage>2393</fpage><lpage>2404</lpage><pub-id pub-id-type="pmid">15571588</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lohmueller</surname><given-names>KE</given-names></name><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Pike</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name></person-group><article-title>Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease</article-title><source>Nat Genet</source><year>2003</year><volume>33</volume><issue>2</issue><fpage>177</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12524541</pub-id></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><article-title>A haplotype map of the human genome</article-title><source>Nature</source><year>2005</year><volume>437</volume><issue>7063</issue><fpage>1299</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">16255080</pub-id></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells</article-title><source>Immunogenetics</source><year>2006</year><volume>57</volume><issue>12</issue><fpage>934</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">16372191</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>BS</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name></person-group><article-title>Understanding the IL-23-IL-17 immune pathway</article-title><source>Trends Immunol</source><year>2006</year><volume>27</volume><issue>1</issue><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16290228</pub-id></citation></ref><ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oppmann</surname><given-names>B</given-names></name><name><surname>Lesley</surname><given-names>R</given-names></name><name><surname>Blom</surname><given-names>B</given-names></name><name><surname>Timans</surname><given-names>JC</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hunte</surname><given-names>B</given-names></name><name><surname>Vega</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Zonin</surname><given-names>F</given-names></name><name><surname>Vaisberg</surname><given-names>E</given-names></name><name><surname>Churakova</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gorman</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Zurawski</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Abrams</surname><given-names>JS</given-names></name><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>Rennick</surname><given-names>D</given-names></name><name><surname>de Waal-Malefyt</surname><given-names>R</given-names></name><name><surname>Hannum</surname><given-names>C</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name></person-group><article-title>Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12</article-title><source>Immunity</source><year>2000</year><volume>13</volume><issue>5</issue><fpage>715</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11114383</pub-id></citation></ref><ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>D</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Scheerens</surname><given-names>H</given-names></name><name><surname>Poulet</surname><given-names>F</given-names></name><name><surname>McClanahan</surname><given-names>T</given-names></name><name><surname>McKenzie</surname><given-names>B</given-names></name><name><surname>Kleinschek</surname><given-names>MA</given-names></name><name><surname>Owyang</surname><given-names>A</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Blumenschein</surname><given-names>W</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Sathe</surname><given-names>M</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name><name><surname>Rennick</surname><given-names>D</given-names></name></person-group><article-title>IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><issue>5</issue><fpage>1310</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16670770</pub-id></citation></ref><ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hue</surname><given-names>S</given-names></name><name><surname>Ahern</surname><given-names>P</given-names></name><name><surname>Buonocore</surname><given-names>S</given-names></name><name><surname>Kullberg</surname><given-names>MC</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>McKenzie</surname><given-names>BS</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name><name><surname>Maloy</surname><given-names>KJ</given-names></name></person-group><article-title>Interleukin-23 drives innate and T cell-mediated intestinal inflammation</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><issue>11</issue><fpage>2473</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17030949</pub-id></citation></ref><ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Giese</surname><given-names>T</given-names></name><name><surname>Ludwig</surname><given-names>B</given-names></name><name><surname>Mueller-Molaian</surname><given-names>I</given-names></name><name><surname>Marth</surname><given-names>T</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Meuer</surname><given-names>SC</given-names></name><name><surname>Stallmach</surname><given-names>A</given-names></name></person-group><article-title>Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn&#x02019;s disease but not in ulcerative colitis</article-title><source>Inflamm Bowel Dis</source><year>2005</year><volume>11</volume><issue>1</issue><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15674109</pub-id></citation></ref><ref id="R35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Zeiss</surname><given-names>C</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Tsai</surname><given-names>JY</given-names></name><name><surname>Sackler</surname><given-names>RS</given-names></name><name><surname>Haynes</surname><given-names>C</given-names></name><name><surname>Henning</surname><given-names>AK</given-names></name><name><surname>SanGiovanni</surname><given-names>JP</given-names></name><name><surname>Mane</surname><given-names>SM</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Bracken</surname><given-names>MB</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Barnstable</surname><given-names>C</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name></person-group><article-title>Complement factor H polymorphism in age-related macular degeneration</article-title><source>Science</source><year>2005</year><volume>308</volume><issue>5720</issue><fpage>385</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15761122</pub-id></citation></ref><ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Ritter</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Abel</surname><given-names>KJ</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Panhuysen</surname><given-names>C</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name></person-group><article-title>Complement factor H polymorphism and age-related macular degeneration</article-title><source>Science</source><year>2005</year><volume>308</volume><issue>5720</issue><fpage>421</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15761121</pub-id></citation></ref><ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Gallins</surname><given-names>P</given-names></name><name><surname>Spencer</surname><given-names>KL</given-names></name><name><surname>Kwan</surname><given-names>SY</given-names></name><name><surname>Noureddine</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Complement factor H variant increases the risk of age-related macular degeneration</article-title><source>Science</source><year>2005</year><volume>308</volume><issue>5720</issue><fpage>419</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15761120</pub-id></citation></ref></ref-list><sec id="S13" sec-type="display-objects"><title>Tables</title><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic details of 2877 individuals with IBD used in case control panel</p></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"><italic>CD</italic><break/>n = 1902</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>UC</italic><break/>n = 975</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Median age at diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">26 years</td><td align="center" valign="top" rowspan="1" colspan="1">38.9 years</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Gender - female: male</td><td align="center" valign="top" rowspan="1" colspan="1">1153: 745</td><td align="center" valign="top" rowspan="1" colspan="1">480: 495</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Smoking at diagnosis - never</td><td align="center" valign="top" rowspan="1" colspan="1">58.4%</td><td align="center" valign="top" rowspan="1" colspan="1">55.0%</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;ex</td><td align="center" valign="top" rowspan="1" colspan="1">9.4%</td><td align="center" valign="top" rowspan="1" colspan="1">30.3%</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;current</td><td align="center" valign="top" rowspan="1" colspan="1">32.2%</td><td align="center" valign="top" rowspan="1" colspan="1">14.7%</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Jewish ancestry</td><td align="center" valign="top" rowspan="1" colspan="1">1.75%</td><td align="center" valign="top" rowspan="1" colspan="1">1.9%</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Non-Caucasians</td><td align="center" valign="top" rowspan="1" colspan="1">2.25%</td><td align="center" valign="top" rowspan="1" colspan="1">3.25%</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Surgery</td><td align="center" valign="top" rowspan="1" colspan="1">61.8%</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Location / extent</td><td align="center" valign="top" rowspan="1" colspan="1">32.7% ileal</td><td align="center" valign="top" rowspan="1" colspan="1">16.5% rectum only</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">31.8% colonic</td><td align="center" valign="top" rowspan="1" colspan="1">35.0% distal to splenic flexure</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">35.5% ileo-colonic</td><td align="center" valign="top" rowspan="1" colspan="1">48.5% proximal to splenic flexure</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">27.1% perianal</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Behaviour</td><td align="center" valign="top" rowspan="1" colspan="1">36.5% stenosing</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">17.15% penetrating</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><?landscape?><label>Table 2</label><caption><p>Case/control allele frequencies and disease odds ratios (95% confidence intervals) for CD and UC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">SNP</th><th align="center" valign="middle" rowspan="1" colspan="1">Allele</th><th align="center" valign="middle" rowspan="1" colspan="1">Controls</th><th align="center" valign="middle" rowspan="1" colspan="1">CD</th><th align="center" valign="middle" rowspan="1" colspan="1">P</th><th align="center" valign="middle" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1">UC</th><th align="center" valign="middle" rowspan="1" colspan="1">p</th><th align="center" valign="middle" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs1004819</td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">0.307</td><td align="center" valign="middle" rowspan="1" colspan="1">0.383</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1&#x000d7;10<sup>-8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 (1.23, 1.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.348</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00713</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20 (1.05, 1.37)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs10489629</td><td align="center" valign="middle" rowspan="1" colspan="1">G</td><td align="center" valign="middle" rowspan="1" colspan="1">0.448</td><td align="center" valign="middle" rowspan="1" colspan="1">0.372</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8&#x000d7;10<sup>-8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 (0.66, 0.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.82, 1.05)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs11465804</td><td align="center" valign="middle" rowspan="1" colspan="1">G</td><td align="center" valign="middle" rowspan="1" colspan="1">0.058</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">7.2&#x000d7;10<sup>-11</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.41 (0.31, 0.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">0.081</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 (0.58, 1.02)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs11209026</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1&#x000d7;10<sup>-12</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.38 (0.29, 0.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0291</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 (0.55, 0.96)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs1343151</td><td align="center" valign="middle" rowspan="1" colspan="1">T</td><td align="center" valign="middle" rowspan="1" colspan="1">0.332</td><td align="center" valign="middle" rowspan="1" colspan="1">0.266</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1&#x000d7;10<sup>-7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 (0.65, 0.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.315</td><td align="center" valign="middle" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.81, 1.06)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs10889677</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.315</td><td align="center" valign="middle" rowspan="1" colspan="1">0.398</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4&#x000d7;10<sup>-10</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.45 (1.28, 1.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.358</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0042</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22 (1.07, 1.39)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs11209032</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.320</td><td align="center" valign="middle" rowspan="1" colspan="1">0.390</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3&#x000d7;10<sup>-7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (1.22, 1.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3524</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 (1.01, 1.32)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs1495965</td><td align="center" valign="middle" rowspan="1" colspan="1">G</td><td align="center" valign="middle" rowspan="1" colspan="1">0.447</td><td align="center" valign="middle" rowspan="1" colspan="1">0.517</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4&#x000d7;10<sup>-7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.32 (1.19, 1.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.457</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 (0.92, 1.18)</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><?landscape?><label>Table 3</label><caption><p>Arg381Gln genotype and allele frequencies in CD cases stratified by known phenotypic subgroups and <italic>CARD15</italic> status</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">AA</th><th align="center" valign="top" rowspan="1" colspan="1">AG</th><th align="center" valign="top" rowspan="1" colspan="1">GG</th><th align="center" valign="top" rowspan="1" colspan="1">Total</th><th align="center" valign="top" rowspan="1" colspan="1">Freq(A)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Gender</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Male<break/>Female</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>2</td><td align="center" valign="top" rowspan="1" colspan="1">36<break/>49</td><td align="center" valign="top" rowspan="1" colspan="1">690<break/>1068</td><td align="center" valign="top" rowspan="1" colspan="1">727<break/>1119</td><td align="center" valign="top" rowspan="1" colspan="1">0.026<break/>0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Smoking History</bold></td><td align="left" valign="top" rowspan="1" colspan="1">No<break/>Yes<break/>Ex</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>1<break/>0</td><td align="center" valign="top" rowspan="1" colspan="1">28<break/>21<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">729<break/>414<break/>127</td><td align="center" valign="top" rowspan="1" colspan="1">758<break/>436<break/>128</td><td align="center" valign="top" rowspan="1" colspan="1">0.020<break/>0.026<break/>0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Disease Location</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Pure colorectal disease<break/>Pure Ileal Disease<break/>Ileo-Colonic disease<break/>Any colorectal disease<break/>Any ileal disease</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>0<break/>1<break/>2<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">23<break/>31<break/>25<break/>46<break/>54</td><td align="center" valign="top" rowspan="1" colspan="1">515<break/>533<break/>642<break/>1101<break/>1115</td><td align="center" valign="top" rowspan="1" colspan="1">539<break/>564<break/>668<break/>1149<break/>1170</td><td align="center" valign="top" rowspan="1" colspan="1">0.023<break/>0.027<break/>0.020<break/>0.022<break/>0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Perianal Disease</bold></td><td align="left" valign="top" rowspan="1" colspan="1">yes<break/>no</td><td align="center" valign="top" rowspan="1" colspan="1">2<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">20<break/>59</td><td align="center" valign="top" rowspan="1" colspan="1">454<break/>1205</td><td align="center" valign="top" rowspan="1" colspan="1">476<break/>1265</td><td align="center" valign="top" rowspan="1" colspan="1">0.025<break/>0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Disease Behaviour</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Stenosing<break/>Penetrating<break/>Inflammatory only</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>2<break/>0</td><td align="center" valign="top" rowspan="1" colspan="1">32<break/>15<break/>30</td><td align="center" valign="top" rowspan="1" colspan="1">604<break/>248<break/>714</td><td align="center" valign="top" rowspan="1" colspan="1">637<break/>265<break/>744</td><td align="center" valign="top" rowspan="1" colspan="1">0.027<break/>0.036<break/>0.020</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Surgery</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Yes<break/>No</td><td align="center" valign="top" rowspan="1" colspan="1">2<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">51<break/>31</td><td align="center" valign="top" rowspan="1" colspan="1">1035<break/>645</td><td align="center" valign="top" rowspan="1" colspan="1">1088<break/>677</td><td align="center" valign="top" rowspan="1" colspan="1">0.025<break/>0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age at diagnosis</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>&#x02264; 16</bold><break/><bold>17-40</bold><break/><bold>&#x0003e;40</bold></td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>2<break/>0</td><td align="center" valign="top" rowspan="1" colspan="1">8<break/>60<break/>14</td><td align="center" valign="top" rowspan="1" colspan="1">197<break/>1129<break/>324</td><td align="center" valign="top" rowspan="1" colspan="1">206<break/>1191<break/>338</td><td align="center" valign="top" rowspan="1" colspan="1">0.024<break/>0.027<break/>0.021</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>CARD15 Status</bold><xref ref-type="table-fn" rid="TFN1">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">-/-<break/>-/+<break/>+/+</td><td align="center" valign="top" rowspan="1" colspan="1">3<break/>0<break/>0</td><td align="center" valign="top" rowspan="1" colspan="1">52<break/>15<break/>5</td><td align="center" valign="top" rowspan="1" colspan="1">1025<break/>342<break/>98</td><td align="center" valign="top" rowspan="1" colspan="1">1080<break/>357<break/>103</td><td align="center" valign="top" rowspan="1" colspan="1">0.027<break/>0.021<break/>0.024</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P32">Samples are subdivided by CARD 15 status into those homozygous wildtype (-/-), those heterozygous for CD associated variants (-/+) and those which are homozygous or compound heterozygous for CD associated variants (+/+)</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><?landscape?><label>Table 4</label><caption><p>Arg381Gln genotype and allele frequencies in UC cases stratified by known phenotypic subgroups</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">AA</th><th align="center" valign="top" rowspan="1" colspan="1">AG</th><th align="center" valign="top" rowspan="1" colspan="1">GG</th><th align="center" valign="top" rowspan="1" colspan="1">Total</th><th align="center" valign="top" rowspan="1" colspan="1">Freq(A)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Gender</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Male<break/>Female</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>2</td><td align="center" valign="top" rowspan="1" colspan="1">41<break/>43</td><td align="center" valign="top" rowspan="1" colspan="1">447<break/>436</td><td align="center" valign="top" rowspan="1" colspan="1">489<break/>481</td><td align="center" valign="top" rowspan="1" colspan="1">0.044<break/>0.049</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Smoking History</bold></td><td align="left" valign="top" rowspan="1" colspan="1">No<break/>Yes<break/>Ex</td><td align="center" valign="top" rowspan="1" colspan="1">0<break/>0<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">28<break/>7<break/>20</td><td align="center" valign="top" rowspan="1" colspan="1">301<break/>81<break/>160</td><td align="center" valign="top" rowspan="1" colspan="1">329<break/>88<break/>181</td><td align="center" valign="top" rowspan="1" colspan="1">0.043<break/>0.040<break/>0.061</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Disease Extent</bold></td><td align="left" valign="top" rowspan="1" colspan="1">Rectum only<break/>Distal to splenic flexure<break/>Proximal to splenic flexure</td><td align="center" valign="top" rowspan="1" colspan="1">1<break/>1<break/>1</td><td align="center" valign="top" rowspan="1" colspan="1">12<break/>24<break/>43</td><td align="center" valign="top" rowspan="1" colspan="1">134<break/>286<break/>387</td><td align="center" valign="top" rowspan="1" colspan="1">147<break/>311<break/>431</td><td align="center" valign="top" rowspan="1" colspan="1">0.048<break/>0.042<break/>0.052</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age at diagnosis</bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>&#x02264; 16</bold><break/><bold>17-40</bold><break/><bold>&#x0003e;40</bold></td><td align="center" valign="top" rowspan="1" colspan="1">0<break/>1<break/>0</td><td align="center" valign="top" rowspan="1" colspan="1">2<break/>41<break/>28</td><td align="center" valign="top" rowspan="1" colspan="1">39<break/>443<break/>228</td><td align="center" valign="top" rowspan="1" colspan="1">41<break/>485<break/>256</td><td align="center" valign="top" rowspan="1" colspan="1">0.025<break/>0.044<break/>0.055</td></tr></tbody></table></table-wrap></sec></back></article> 